Symbolbild · KI-generiert
Akebia Therapeutics, Inc.
Stock factsheet
Company data from public sources (TMX Money, Canadian Securities Exchange, Nasdaq screener, Wikidata); every ISIN is verified against its check digit. Where „—“ appears, no verified value exists — we do not publish unverified identifiers. Market capitalisation is an order of magnitude as of the date shown, not a real-time figure. The size class follows the thresholds in common use (micro < $300m, small < $2bn, mid < $10bn) and is meant as an indication, not a definition.
Company profile
Akebia Therapeutics is a biopharmaceutical company focused on the development and commercialisation of therapies for kidney diseases. Its core product Vafseo (Vadadustat) is an oral HIF prolyl hydroxylase inhibitor for the treatment of anaemia in chronic kidney disease.
Short profile generated automatically and checked for plausibility. A full editorial profile follows once we cover the company.
Share price
Price data from TradingView, possibly delayed. Not investment advice.
Comparable companies
Companies in the Biotech & Pharma sector of a similar size.
| Company | Ticker | Exchange | Market cap |
|---|---|---|---|
| Akebia Therapeutics, Inc. | AKBA | NASDAQ | 354 Mio. USD |
| Fennec Pharmaceuticals Inc. | FRX | TSX | 346 Mio. USD |
| Tenax Therapeutics, Inc. | TENX | NASDAQ | 363 Mio. USD |
| Compass Therapeutics, Inc. | CMPX | NASDAQ | 344 Mio. USD |
| Century Therapeutics, Inc. | IPSC | NASDAQ | 364 Mio. USD |
| TECSYS Inc. | TCS | TSX | 344 Mio. USD |
| Upstream Bio, Inc. | UPB | NASDAQ | 343 Mio. USD |
Investor Relations
We link only to primary sources from the company itself and from the regulators. Fields we have not recorded stay empty until a reliable source is available.
Information and education only — not investment advice, not a recommendation and not a financial analysis within the meaning of §85 WpHG or Art. 20 MAR. Investments in small and micro caps are highly speculative; total loss is possible. All information without warranty.